Franklin Resources’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Franklin Resources’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-300,000	Closed	-$109K	–	2442
2022 Q2	$109K	Sell	300,000 -613,576	-67%	-$310K	﹤0.01%	2135
2022 Q1	$621K	Sell	913,576 -685,119	-43%	-$752K	﹤0.01%	1755
2021 Q4	$3.69M	Buy	1,598,695 +51	+0%	+$173	﹤0.01%	1313
2021 Q3	$7.32M	Hold	1,598,644	–	–	﹤0.01%	1124
2021 Q2	$7.1M	Hold	1,598,644	–	–	﹤0.01%	1072
2021 Q1	$11.6M	Hold	1,598,644	–	–	﹤0.01%	944
2020 Q4	$12.2M	Buy	1,598,644 +898,644	+128%	+$6.01M	0.01%	920
2020 Q3	$6.36M	Hold	700,000	–	–	﹤0.01%	999
2020 Q2	$6.29M	Hold	700,000	–	–	﹤0.01%	963
2020 Q1	$3.46M	Hold	700,000	–	–	﹤0.01%	995
2019 Q4	$5.04M	Hold	700,000	–	–	﹤0.01%	1014
2019 Q3	$7.57M	Hold	700,000	–	–	﹤0.01%	922
2019 Q2	$9.1M	Hold	700,000	–	–	﹤0.01%	916
2019 Q1	$6.92M	Hold	700,000	–	–	﹤0.01%	953
2018 Q4	$7.28M	Buy	+700,000	New	+$8.46M	﹤0.01%	928

Other funds holding LOGC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Franklin Resources's LOGC Position: Q3 2022 in Review

Franklin Resources sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q3 2022, closing a stake of 300,000 shares — an estimated $109K sold.

Franklin Resources first reported a position in LOGC in Q4 2018 and held it in 15 quarters. The position peaked at $12.2M in Q4 2020. 39 funds tracked by Wall St. Rank hold LOGC as of Q3 2022.

Franklin Resources reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Franklin Resources sold 300,000 LogicBio Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $109K.
Franklin Resources first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 15 quarters.
Franklin Resources's LogicBio Therapeutics, Inc. Common Stock position peaked at $12.2M in Q4 2020.
39 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Franklin Resources's 13F filing for Q3 2022, filed 14 Nov 2022.